What’s Next in Pharmaceutical R&D? A Conversation with Upperton’s Director of Pharmaceutical Sciences
We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.
Insight
Does a One-Site CDMO Make a Difference in Drug Development?
A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.
Tech Transfer in Late-Stage Oral Solid Dose Projects: Lessons Learnt and Best Practices from a CDMO Perspective
Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the drug development lifecycle. For CDMOs, it’s a moment where scientific precision meets operational discipline.
How to Evaluate CDMO Communication Before You Commit: A Framework for Biotechs
By using our framework , sponsors can identify partners who don’t just deliver projects, but build relationships that last.
From Molecule to Market: Understanding the Roles of CROs, CMOs, and CDMOs
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Sniffing Out Solutions in the Nasal Drug Delivery Revolution
The nose to brain pathway can be leveraged to unlock new therapeutic possibilities. Learn about the opportunities of N2B delivery.
What to Expect from Upperton at CPHI Frankfurt 2025
CPHI Frankfurt is one of the most anticipated events in the pharmaceutical calendar. Upperton is proud to be exhibiting.
The New Rules of CDMO Partnerships: What Biotechs Should Be Looking for Next
Biotech companies today seek long-term development partners who can help to de-risk supply chains, accelerate time-to-market.
The Bright Side of Biologic Stability: A Thermofluor Screen for Rational Buffer Optimisation
Learn about the challenges of stabilising injectable biologics.
Biologics vs Small Molecules: Key Considerations in Drug Development
How the body absorbs, distributes, metabolizes, and excretes a drug – differs significantly between the two modalities.